



Program Announcement for the Defense Health Agency

Peer Reviewed Medical Research Program

Technology/Therapeutic Development Award

Funding Opportunity Number: HT942526PRMRPTTDA

Pre-Application Due: July 23, 2026

Application Due: August 6, 2026

This program announcement must be read in conjunction with the General Application Instructions, version [CD26_01](#).

Content

	Before You Begin	3
①	Basic Information Summarizes the <u>funding opportunity</u> , <u>funding details</u> , <u>submission deadlines and review dates</u>	4
②	Eligibility Details eligibility factors for the <u>applicant organization</u> and <u>Principal Investigator</u>	5
③	Program Description Describes the <u>program mission</u> and <u>intent</u> of the <u>Technology/Therapeutic Development Award</u> ; provides <u>key award information</u> and <u>considerations</u> ; and outlines <u>funding details</u>	6
④	Application Contents Presents the two-step <u>application process</u> and instructions for preparing a <u>pre-application</u> and <u>full application</u>	21
⑤	Submission Requirements Provides <u>locations for application packages</u> , instructions for submitting <u>pre-applications</u> and <u>full applications</u> , and describes <u>application verification</u>	30
⑥	Application Review Information Outlines the processes for application <u>compliance review</u> , <u>pre-application</u> and <u>full application</u> selection/notification, and <u>risk assessment</u> . Also, details the review criteria for <u>pre-application screening</u> and both tiers of the CDMRP application review process – <u>Peer Review</u> and <u>Programmatic Review</u>	32
⑦	Federal Award Notices Outlines what a successful applicant can expect <u>if recommended for funding</u>	37
⑧	Post-Award Requirements References <u>policy requirements</u> for funded research; outlines <u>reporting requirements</u> and restrictions related to <u>Principal Investigator changes</u> and <u>institutional award transfers</u>	38
⑨	Other Information Outlines criteria for administrative actions including application <u>rejection</u> , <u>modification</u> , <u>withdrawal</u> and <u>withhold</u>	40
	Appendix 1 Includes a checklist for all full application components to facilitate application submission	42
	Appendix 2 Acronym List	43
	Appendix 3 Change Log	45

Before You Begin

- **Active [SAM.gov](#), [eBRAP.org](#) and [Grants.gov](#) registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process [FAQ](#), a [Guide for Intragovernmental & Intramural Applicants](#) and a [CDMRP Video Series](#) detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

*Questions regarding
funding opportunity submission
requirements,
as well as technical assistance
related to pre-application or
intramural application submission.*

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

*Questions regarding
Grants.gov registration
and Workspace.*

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click  to be taken to additional guidance and instructions within the *General Application Instructions (GAI)*.

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#) | [Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award, a product-driven award mechanism, intends to support the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision-making tools or practice guidelines. Products in development should address or have dual purpose potential for the health care needs of military Service Members, Veterans and their Families.

Distinctive Features: For the PRMRP Technology/Therapeutic Development Award, the program expects the research proposed will take an ***already established proof-of-concept or prototype*** through the final stages of preclinical development. The PRMRP also expects that the research outcome will be a ***regulatory filing or translation of findings into clinical practice***, as applicable.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly \$67.2M to fund approximately 12 Technology/Therapeutic Development Award applications with total cost caps of \$5.6M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Letter of Intent) Submission Deadline:** 5:00 p.m. Eastern Time (ET), July 23, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, August 6, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, August 13, 2026
- **Peer Review:** October/November 2026
- **Programmatic Review:** February/March 2027

Announcement Type: Modified

Funding Opportunity Number: HT942526PRMRPTTDA

Assistance Listing Number: 12.420

Section Shortcuts

Basic Information | [Eligibility](#) | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

[Extramural](#) and [intramural U.S. Department of War \(DOW\)](#) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.***

2.1.2. Principal Investigator

Independent investigators (e.g., Assistant Professor, Senior Scientist, Principal Scientist, Research Director, or equivalent) may be named by the organization as the Principal Investigator (PI) on the application.

Each investigator may be named on only one FY26 PRMRP application as a PI. If more than one pre-application submitted to the FY26 PRMRP names the same PI, the first submission will be accepted, and subsequent submissions will be administratively withdrawn.

Independent investigators affiliated with an eligible organization are eligible to be named PI on the application, regardless of ethnicity, nationality or citizenship status.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional [recipient qualification requirements](#).

Section Shortcuts


Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Peer Reviewed Medical Research Program (PRMRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the PRMRP in 1999 to support medical research projects of clear scientific merit and direct relevance to military health. Appropriations for the PRMRP from FY99 through FY25 totaled \$4.34 billion. The FY26 appropriation is \$370 million.

FY26 PRMRP Research Development Pipeline

To address the congressionally directed FY26 PRMRP topic areas in a bench-to-bedside fashion, the FY26 PRMRP award mechanisms are aligned to different phases of the research development pipeline illustrated below.



The **Use-Inspired Basic Research** phase represents novel, exploratory research aimed at generating preliminary data and/or preclinical research that is ready for validation through expansion, replication, or comparative studies. While projects may be aiming to understand fundamental physiological phenomena, “basic research,” they should be driven by a specific clinical need and potential application, “use-inspired.” Applicants seeking support for research aligning to the Use-Inspired Basic Research phase may consider:

- **FY26 PRMRP Discovery Award** (HT942526PRMRPDA) for novel, high-risk, high reward research projects with the potential to yield high-impact findings and new avenues of investigation. Preliminary data is not allowed.
- **FY26 PRMRP Research Advancement Award** (HT942526PRMRPRAA) for building upon existing preliminary data to validate a concept.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

The **Translational Research** phase seeks to transition scientific data towards treatment, diagnostic and/or preventive strategies. Research projects are expected to have significant near-term impact on patients' lives. Examples of projects in the translational phase include product/device development and clinical translation of concepts previously validated through expansion, replication or comparative studies. Applicants seeking support for research aligning to the Translational Research phase may consider:

- **FY26 PRMRP Impact Award** (HT942526PRMRPIPA) for mature research projects that are ready to translate ideas into solutions. Initial product discovery, development, and optimization are supported.
- **FY26 PRMRP Technology/Therapeutic Development Award** (HT942526PRMRPTTDA) for finalizing preclinical development of tangible products (drugs or biologics), knowledge-based products and/or devices. The research outcome should be a regulatory filing or translation of findings into clinical practice, as applicable.

The **Translational to Clinical Transition** phase represents the final stages of product development with early, phase 0/1, or equivalent, clinical trials. Products may include both knowledge and tangible items that will be used to impact patient care.

- **FY26 PRMRP Platform Clinical Translation Award** (HT942526PRMRPPCTA) for finalizing preclinical development, conducting clinical validation studies, and/or conducting first in human clinical trials for a platform product with the potential to impact clinical care for two or more FY26 PRMRP topic areas.

The **Clinical Research** phase represents small- and large-scale confirmatory trials and/or applied clinical research that will revolutionize the clinical management of the diseases and conditions assigned to the program as topic areas. Applicants seeking support for trials and studies aligned to the Clinical Research phase may consider:

- **FY26 PRMRP Lifestyle and Applied Health Research Award** (HT942526PRMRPLAHRA) for clinical trials focused on efficacy of non-pharmacological interventions or noninvasive devices or clinical research to examine the impact of prevention, diagnostic, treatment or health care delivery approaches on health outcomes. Animal research is not allowed.
- **FY26 PRMRP Clinical Trial Award** (HT942526PRMRPCTA) for projects to determine the safety or efficacy outcomes of pharmacological interventions, devices or implants on prospectively recruited human participants. Animal research, preclinical experiments, and optimization/validation of the intervention are not allowed.

NOTE: The scope of research proposed in applications in response to the FY26 PRMRP program announcements must align with the research phases outlined above. It is the responsibility of the applicant to select the award mechanism that aligns with the scope of the proposed research. The funding mechanism should be selected based on the research scope defined in the program announcement, and not on the amount of the budget. Applications submitted under a mechanism that is not deemed appropriate for the scope of research proposed will not be funded.

3.1. Award History

The PRMRP first offered the Technology/Therapeutic Development Award (TTDA) mechanism in FY08. In FY21, the TTDA offered two funding levels based on the scope of research. Starting in FY24, the TTDA only supported research in the final stages of preclinical development, previously referred to as Funding Level 2, and this continues for FY26.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

3.2. Intent of the Technology/Therapeutic Development Award

The PRMRP TTDA, a product-driven award mechanism, intends to support the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP portfolio-specific strategic goals. The proposed experiments may be hypothesis or milestone driven, and should encompass all of the experiments necessary to move the product into clinical trials or implementation into clinical practice. Products in development should address or have dual purpose potential for the health care needs of military Service Members, Veterans and their Families. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision-making tools or practice guidelines. (A “knowledge product” is a non-materiel product that addresses an identified need in a topic area, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)

The PRMRP TTDA is not intended to support initial product discovery and is not intended to support products for research use only. Products should be supported by strong preliminary data demonstrating the potential for clinical translation in the near term. Preliminary data may include published data from the scientific literature and/or unpublished data from the laboratory of the PI or a member of the research team. For interventional products that will be regulated by the U.S. Food and Drug Administration (FDA), or equivalent, it is expected that the research outcome will be a regulatory filing. Applicants seeking funding for research products, initial product discovery, or that will not be able to take their product all of the way through the final stages of preclinical development should consider one of the other FY26 PRMRP program announcements being offered. For information about these award mechanisms, see information contained in the [FY26 PRMRP Research Development Pipeline](#).

3.2.1. FY26 PRMRP Topic Areas and Strategic Goals

To meet the intent of the funding opportunity, ***all applications for FY26 PRMRP funding must specifically address one of the FY26 PRMRP topic areas as directed by the U.S. Congress and have direct relevance to military health.*** Additionally, the PRMRP implements a portfolio-driven approach by grouping related topic areas with strategic goals as a framework within which to address critical gaps in major research areas. ***All applications must address one of the FY26 PRMRP strategic goals as it relates to the portfolio-assigned FY26 PRMRP topic area. The FY26 PRMRP strategic goals for each portfolio are aligned to the categories of the continuum of care (foundational studies, epidemiology, prevention, diagnosis and treatment).*** If the proposed research does not specifically address one FY26 PRMRP topic area and one FY26 PRMRP strategic goal, then the government reserves the right to administratively withdraw the application. The government reserves the right to reassign the application’s topic area if submitted to an incorrect topic area. The section below lists the FY26 PRMRP topic areas and strategic goals in each PRMRP portfolio category.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 PRMRP Portfolio Categories With Associated FY26 PRMRP Topic Areas and FY26 PRMRP Strategic Goals

AUTOIMMUNE DISORDERS AND IMMUNOLOGY

All applications under this portfolio must be aligned to Autoimmune Disorders and Immunology by addressing one topic area and one strategic goal listed below.

TOPIC AREAS

- Celiac Disease
- Eczema
- Food Allergies
- Inflammatory Bowel Disease
- Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS)
- Sarcoidosis
- Scleroderma

STRATEGIC GOALS BY CONTINUUM OF CARE

Foundational Studies

- Investigate the mechanisms driving the pathobiology of the disease/condition.
- Investigate factors affecting disease/condition onset, progression, or heterogeneity, such as environmental exposures, comorbidities, behaviors, genetics, stress, infections, neuroimmune interactions, or microbiome dynamics.
- Investigate sex differences in the immune system.

Epidemiology

- Conduct patient-centered research to identify factors driving incidence trends, including recent increases.
- Conduct patient-centered studies to better understand differences between childhood- and adult-onset immune-mediated diseases/conditions, focusing on underlying pathobiology and treatment response.
- Conduct population-based studies to identify risk factors and enhance methods for detecting individuals at high risk.
- Conduct research to better understand sex differences in incidence and/or outcomes.
- Conduct population-based studies to examine variations in incidence and outcomes across different population subgroups.

Prevention

- Develop and test innovative strategies to prevent the onset, relapse, and/or progression of the disease/condition.
- Identify and test approaches to establish immune tolerance early in life.

Diagnosis

- Identify and validate biomarkers for continuous monitoring of disease/condition progression or to evaluate intervention response.
- Develop and validate improved diagnostic tools to enable early, accurate detection and to standardize diagnostic strategies.

Treatment

- Develop and test curative and immune reset interventions.
- Develop and test therapies effective across all or multiple allergens or autoantigens.
- Develop and test strategies to improve outcomes, reduce inflammation, promote healing, provide neuroprotection, delay symptom onset, or minimize toxicity, including lifestyle changes, targeted drugs, nutraceuticals, and personalized treatments.
- Generate evidence for repurposing and off-label use of potential treatments.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

CARDIOVASCULAR HEALTH

All applications under this portfolio must be aligned to Cardiovascular Health by addressing one topic area and one strategic goal listed below.

TOPIC AREAS

- Brain Injury Impact on Cardiac Health
- Hypoxia

STRATEGIC GOALS BY CONTINUUM OF CARE

Foundational Studies

- Investigate the mechanisms driving the pathobiology of the disease/condition.
- Investigate the mechanisms driving cardiovascular dysfunction following brain injury.
- Enhance understanding of oxygen sensing and the biological response to low oxygen levels.
- Identify risk factors, with a focus on comorbidities and genetic predispositions.

Epidemiology

- Conduct population-based studies to monitor cardiovascular changes over time.
- Conduct population-based research to identify risk factors, including but not limited to brain injury, and improve methods to detect individuals at high risk.
- Conduct population-based studies to examine variations in incidence and outcomes across different population subgroups.

Prevention

- Develop and test strategies to prevent or reduce the impact of the disease/condition on the heart, brain, arteries, and additional target organs.
- Develop and test strategies to reduce/prevent risk factors associated with disease onset, progression, or complications.

Diagnosis

- Develop and test strategies to enhance detection accuracy and sensitivity, including strategies to identify maladaptive vascular remodeling or to enable continuous monitoring or detection of tissue- or cell-specific oxygen levels.
- Develop and validate less invasive diagnostic methods.
- Identify and validate biomarkers that reliably predict outcomes.

Treatment

- Generate evidence to support the repurposing and off-label use of treatments, including research on optimal dosing regimens.
- Develop and test innovative therapeutic strategies, with an emphasis on targeted, localized, and personalized approaches.

INFECTIOUS DISEASES

All applications under this portfolio must be aligned to Infectious Diseases by addressing one topic area and one strategic goal listed below.

TOPIC AREAS

- Congenital Cytomegalovirus
- Tuberculosis
- Hepatitis B

STRATEGIC GOALS BY CONTINUUM OF CARE

Foundational Studies

- Investigate the mechanisms of infection, transmission, pathogenicity, or drug resistance.
- Develop innovative preclinical models to investigate disease pathobiology, host response, and to support drug discovery and testing.
- Enhance understanding of interactions between infection and comorbid conditions.
- Identify risk factors contributing to adverse outcomes.
- Discover and evaluate new drug targets.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Epidemiology

- Conduct population-based studies to collect data on disease trends, including those establishing, affiliated with, or contributing to clinical networks, biorepositories, or databanks.
- Conduct population-based studies to improve understanding of transmission, disease progression, and risk factors for complications.
- Conduct retrospective studies to assess the impacts of disease on quality of life.

Prevention

- Develop and test strategies to prevent complications and adverse outcomes following infection.
- Develop and test innovative strategies to prevent disease onset or inhibit its progression.
- Develop and test methods to eliminate maternal-fetal transmission.

Diagnosis

- Develop and validate innovative diagnostic tools, focusing on less- or non-invasive methods, point-of-care applications, early detection, or improved sensitivity.
- Identify and validate biomarkers to improve infection diagnosis and/or prognosis, assess infection-related complications, or measure protection against infection.

Treatment

- Develop and test curative interventions or treatments that eliminate all symptoms, including precision medicine approaches and those that address latent infection.
- Develop and assess new therapeutic strategies that are more potent, act directly, require shorter dosing regimens, provide longer-lasting effects, better mitigate complications, address treatment resistance, and/or address latent infection.
- Generate evidence for optimal treatment regimens, including strategies tailored to specific age groups, combination therapies, and antiviral or vaccine dosing schedule recommendations.

INTERNAL MEDICINE

All applications under this portfolio must be aligned to Internal Medicine by addressing one topic area and one strategic goal listed below.

TOPIC AREAS

- Accelerated Aging Processes Associated with Military Service
- Endometriosis
- Hypertrophic Dyschromia
- Infertility Associated with Military Aviators and Aviation Support Personnel
- Interstitial Cystitis
- Pancreatitis
- Polycystic Kidney Disease

STRATEGIC GOALS BY CONTINUUM OF CARE

Foundational Studies

- Improve understanding of how military service or exposures contribute to physiological dysregulation, reproductive health issues, the aging process, and epigenetic changes.
- Investigate the mechanisms and pathophysiology underlying disease onset and/or progression.
- Improve understanding of disease/condition heterogeneity, comorbidities, systemic impacts, and long-term complications.

Epidemiology

- Conduct comparative studies to determine military-specific risks and enhance understanding diseases/conditions that have increased incidence in the active duty and Veteran population.
- Conduct population- and/or patient-based studies to improve understanding of disease heterogeneity and phenotypic variability.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Conduct research to better understand sex differences in incidence and/or outcomes.
- Conduct population-, occupational-, and/or patient-based studies to identify risk factors that influence disease development, progression, treatment, and outcomes.

Prevention

- Develop and test strategies to reduce the health impacts of military service and exposures and prevent long-term consequences.
- Develop and test innovative strategies to prevent disease onset, progression, and/or associated comorbidities.

Diagnosis

- Develop and validate screening tools to detect conditions associated with premature aging processes.
- Develop and validate innovative diagnostic approaches, focusing on less invasive methods, faster timelines, and methods that account for disease heterogeneity.
- Develop and validate biomarkers, imaging techniques, or other tools for diagnosis, objective prognosis, subtype differentiation, monitoring, or assessing treatment response.
- Develop and validate methods for identifying and measuring toxic agents and their pathophysiological effects.

Treatment

- Develop and test efficacy of lifestyle and other non-drug interventions.
- Develop and test novel treatment strategies aimed at cures or improved symptom management to enhance quality of life, including drug repurposing studies, combination therapies, and innovative drug delivery techniques.
- Develop and assess strategies to enable personalized care recommendations or optimize treatments for specific population subgroups, including studies on the efficacy of existing treatment options.
- Develop and test innovative approaches for pain management as a symptom of the disease/condition.
- Develop and test innovative approaches to improve organ transplant outcomes or transplant alternatives, such as artificial organs, xenotransplants, and novel strategies to prevent rejection.

NEUROSCIENCE AND MENTAL HEALTH

All applications under this portfolio must be aligned to Neuroscience and Mental Health by addressing one topic area and one strategic goal listed below.

TOPIC AREAS

- Brain Injury Impact on Cardiac Health
- Dystonia
- Eating Disorders
- Gambling Addiction
- Hydrocephalus
- Intranasal Ketamine Anesthetics
- Maternal Mental Health
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- PANS and PANDAS
- Peripheral Neuropathy
- Post-Traumatic Stress Disorder
- Sleep Disorders and Restrictions
- Suicide Prevention

STRATEGIC GOALS BY CONTINUUM OF CARE

Foundational Studies

- Investigate the mechanisms underlying disease/condition pathobiology, progression, and associated comorbidities at multi-organ/system, circuit, or cellular/molecular levels.
- Identify factors that predispose individuals to the disease/condition, predict adverse outcomes, or contribute to resilience.
- Enhance understanding of disease/condition heterogeneity, including variations in phenotypic, symptom, and behavioral presentation.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Develop and evaluate innovative models that can be used to understand etiology and will facilitate drug discovery and testing.

Epidemiology

- Conduct population-based studies to identify and track trends and treatment responses, generating data on treatment efficacy to inform the development of personalized treatments.
- Conduct population-based studies to enhance understanding of risk factors and progression of disease/condition.
- Conduct comparative studies to identify military-specific aspects of diseases/conditions, including risk factors, comorbidities, quality of life impacts, treatment preferences, prevalence, and ability to return to duty.
- Conduct research to better understand sex differences in incidence and/or outcomes.
- Conduct population-based studies to examine variations in incidence and outcomes across different population subgroups.

Prevention

- Develop and test strategies to prevent the disease/condition, as well as its downstream complications, including methods for relapse prevention or mitigation of risk factors.
- Develop and test innovative strategies to maintain optimal cognitive functioning and mental resilience.

Diagnosis

- Develop and validate objective diagnostic methods that are accurate, sensitive, enable early detection, and account for heterogeneity in disease/condition phenotypes, includes screening tools.
- Identify and validate biomarkers that predict risk for the primary disease/condition and its secondary complications.
- Develop and validate methods for continuous monitoring and evaluating treatment efficacy.

Treatment

- Develop and test treatments to achieve curative or regenerative outcomes, preserve cognition, and enhance quality of life, including gene therapies, noninvasive stimulation techniques, alternatives to brain surgery, pharmaceuticals, and behavioral interventions.
- Evaluate repurposed drugs to accelerate strategies for improving symptom management and enhancing quality of life.
- Develop and assess guidelines for optimal intervention use, including evidence for safety and efficacy across diverse populations, precision medicine approaches, dosing regimens, safety monitoring, side effect management, and delivery methods.
- Develop and test innovative strategies to increase access to treatments, such as telemedicine approaches and adaptations tailored to specific populations.

ORTHOPAEDIC MEDICINE

All applications under this portfolio must be aligned to Orthopaedic Medicine by addressing one topic area and one strategic goal listed below.

TOPIC AREAS

- Accelerated Aging Processes Associated with Military Service
- Musculoskeletal Health
- Orthotics and Prosthetics Outcomes

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

STRATEGIC GOALS BY CONTINUUM OF CARE

Foundational Studies

- Investigate mechanisms driving musculoskeletal disease/condition pathology and progression, focusing on muscle, connective tissue, genetics, epigenetics, aging, pain, sex differences, physical or mental stress, mechanobiology, cell senescence, and/or systemic interactions.
- Identify risk factors for orthopaedic diseases/conditions, including those that accelerate musculoskeletal degeneration, contribute to adverse outcomes, or lead to more severe symptoms.
- Develop and evaluate disease/injury using preclinical models to improve understanding of mechanisms and support intervention discovery and testing.
- Develop and evaluate small joint disease/injury models improve understanding of mechanisms and support intervention discovery and testing.
- Investigate the impact of life stage impacts musculoskeletal health and related diseases/conditions, including the effects of childhood growth, hormonal changes throughout the lifespan, and aging-related processes.

Epidemiology

- Leverage large data sets to generate evidence-based treatment guidelines to optimize joint longevity.
- Conduct patient-reported outcomes research incorporating both objective measures and quality-of-life metrics to evaluate treatment efficacy and guide intervention decisions.
- Conduct research to better understand sex differences in incidence and/or outcomes.
- Conduct comparative studies to better understand musculoskeletal degeneration in Veterans and identify military-specific risk factors.

Prevention

- Develop and test strategies that improve point-of-injury care, focusing on reducing the risk of secondary complications and promoting joint preservation.
- Optimize and test personalized treatment or rehabilitation plans to address adverse outcomes and mitigate risk factors.
- Develop and test strategies to prevent inflammatory joint damage caused by aging or overuse.

Diagnosis

- Develop and validate strategies for early and precise diagnosis of musculoskeletal dysfunction, including screening methods tailored for pediatric populations.
- Identify and validate biomarkers that indicate the severity or progression rate of musculoskeletal disease or age-associated degeneration.
- Identify and validate biomarkers or outcome measures to monitor disease/condition progression, understand variability, assess treatment efficacy, and evaluate impacts on quality of life.

Treatment

- Advance innovative treatment strategies targeting etiology, preserving joint integrity, retaining functionality for daily activities, improving muscle strength and range of motion, reducing pain or fatigue, and/or regenerating damaged tissues.
- Develop and assess treatment strategies to enhance quality of life by increasing mobility, halting/slowing disease progression, or accelerating return to duty, including exercise regimens, regenerative or immune-modulating therapies, and device optimization.
- Develop and assess methods to optimize treatment, including patient-specific strategies, combination therapies, or refinement of intervention timing and dosing.
- Develop and test improved orthopedic devices, such as AI-driven auto-adjusting devices, better integrated designs for enhanced stability or accelerated healing, improved braces, prosthetic limbs, joint replacements, and strategies to enhance comfort.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

RARE DISEASES AND CONDITIONS

All applications under this portfolio must be aligned to Rare Diseases and Conditions by addressing one topic area and one strategic goal listed below.

TOPIC AREAS

- Angelman Syndrome
- Ehlers-Danlos Syndrome
- Facioscapulohumeral Muscular Dystrophy
- Fibrous Dysplasia/McCune-Albright Syndrome
- Fragile X
- Frontotemporal Degeneration
- Hereditary and Acquired Ataxias
- Hereditary Hemorrhagic Telangiectasia
- Hermansky-Pudlak Syndrome
- Mitochondrial Disease
- Myotonic Dystrophy
- Prader-Willi Syndrome
- Rett Syndrome
- Sickle-Cell Disease
- Spinal Muscular Atrophy
- von Hippel-Lindau Disease

STRATEGIC GOALS BY CONTINUUM OF CARE

Foundational Studies

- Develop and evaluate innovative models for drug discovery and testing, with an emphasis on patient-derived cell models.
- Investigate the mechanisms driving symptoms to identify new strategies for symptom management, including novel drug targets and paradigm-shifting insights into pathobiology.

Epidemiology

- Conduct population- or patient-based studies to evaluate intervention efficacy, incorporating patient-reported outcomes and objective metrics to refine clinical guidance, develop personalized treatments, and validate clinically relevant endpoints.
- Conduct population-based studies to monitor disease progression and identify factors that drive onset, progression, and outcomes.
- Conduct population-based studies to improve understanding of relationships between the disease/condition and comorbidities or conditions with shared symptoms.
- Integrate electronic medical records with real world data to improve the accuracy of prevalence estimates and guide precision medicine approaches.

Prevention

- Develop and test approaches to prevent complications associated with the disease/condition.
- Develop and test approaches, including gene therapy, to prevent symptoms or familial aggregation of the disease/condition.
- Develop and test evidence-based strategies to reduce disease/condition severity, including investigations promoting better health during pregnancy.

Diagnosis

- Develop and validate diagnostic strategies that are objective, noninvasive, accurate, and enable early detection, subtype distinction, disease progression tracking, and complication prediction.
- Develop and validate methods to objectively measure symptoms and evaluate their impact on daily functioning.
- Develop and validate diagnostic, monitoring, or prognostic biomarkers.
- Identify and validate clinically relevant endpoints for assessing treatment response, suitable for use in FDA-regulated clinical trials.

Treatment

- Develop and test innovative treatment approaches, emphasizing early intervention, therapies that slow/halt disease/condition progression, therapies that address phenotypic/subtype differences, and disease-modifying or curative treatments.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Develop and assess strategies to optimize existing treatments to reduce side effects and tailor interventions to specific patients.
- Generate evidence to support and guide the use of off-label drugs for symptom relief.
- Develop and test pharmacological or non-pharmacological interventions to manage symptoms and improve quality of life for patients and caregivers, including strategies for care transitions.

RESEARCH AND CLINICAL TOOLS

All applications under this portfolio must be aligned to Research and Clinical Tools by addressing one topic area and one strategic goal listed below.

TOPIC AREAS

- Proteomics

STRATEGIC GOALS BY CONTINUUM OF CARE

Foundational Studies

- Utilize proteomics to deepen understanding of the molecular mechanisms, progression, comorbidities, and long-term complications of the disease/condition/injury.
- Investigate the functional impact of post-translational modifications and proteoforms, beyond protein abundance, to guide management of the disease/condition/injury.
- Further the integration of proteomic databases and validated proteome subsets into advanced informatics tools.

Epidemiology

- Conduct population-based longitudinal proteomics studies to guide disease/condition/injury management strategies and support the development of personalized care approaches.
- Leverage existing proteomic databases to conduct large-scale research.

Prevention

- Develop and validate proteomics-based technologies to prevent the onset, progression, recurrence, and/or comorbidities of the disease/condition/injury.

Diagnosis

- Develop and validate proteomics-based technologies or biomarkers for early detection, accurate diagnosis, subtype differentiation, monitoring disease/condition progression, or evaluating treatment response.

Treatment

- Develop and test proteomics-based technologies to support personalized treatment strategies.
- Use proteomics-based approaches to identify novel treatments or targets.

RESPIRATORY AND ENVIRONMENTAL HEALTH

All applications under this portfolio must be aligned to Respiratory and Environmental Health by addressing one topic area and one strategic goal listed below.

TOPIC AREAS

- Burn Pit Exposure
- Hypoxia
- Pulmonary Fibrosis
- Respiratory Health

STRATEGIC GOALS BY CONTINUUM OF CARE

Foundational Studies

- Identify factors driving respiratory distress or chronic respiratory disease progression with the goal of identifying novel treatment targets.
- Investigate the mechanisms by which airborne hazards cause respiratory injury/disease, including research linking the toxicant to the specific pathobiology.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Epidemiology

- Conduct population-based studies to generate data on risk factors, disease progression, and treatment outcomes to guide personalized medicine approaches.
- Conduct retrospective studies to correlate toxicant exposure with long-term illnesses.

Prevention

- Develop and test strategies to prevent lung disease following exposure to airborne pollutants, toxicants, or infectious agents.
- Develop and test strategies to prevent the extent of lung damage caused by trauma, transfusion, mechanical ventilation, infection, acute respiratory distress syndrome, or hemorrhagic shock.

Diagnosis

- Identify and validate biomarkers to diagnose, monitor progression, and predict adverse outcomes and complications of chronic respiratory diseases.
- Identify and validate biomarkers to support the development of personalized treatment strategies.
- Develop and validate tools to enable early and accurate detection of respiratory diseases/conditions, focusing on noninvasive approaches and point-of-care strategies.
- Develop and test fieldable toolsets to monitor lung dysfunction.
- Develop and validate methods to quantify individual exposure levels to airborne hazards.

Treatment

- Develop and test innovative treatments to slow progression of the disease/condition and promote lung repair, emphasizing progress towards precision medicine and regenerative approaches.
- Develop and test treatments for respiratory infections.
- Develop and test minimally invasive or noninvasive methods of delivering oxygen and facilitating gas exchange when the lungs are compromised.
- Develop and test fieldable systems to treat lung injury in far-forward settings.

3.2.2. Key Elements for the Technology/Therapeutic Development Award

- **Impact:** The PRMRP TTDA intends to support research that is in the final stages of preclinical development with potential for near-term clinical application. The program expects that the next step after completion of the proposed work includes either a clinical trial or translation into clinical practice, as appropriate for the product under development. The proposed study should demonstrate how the research will lead to the development of a product that will improve patient outcomes in one of the congressionally directed [FY26 PRMRP Topic Areas](#) and address one of the [FY26 PRMRP Strategic Goals](#).
- **Preliminary Data:** The program requires previous establishment of proof of concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from published literature. Unpublished data should originate from the laboratory of the PI or a member of the research team.

Applications supported by this award must begin with lead compounds in hand, a device prototype, or appropriate proof of concept for knowledge products; and must include preliminary data relevant to the phase of development, such as:

- Proof of identity and purity.
- Selectivity for the intended target over closely related targets.

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Availability of primary and secondary in vitro bioactivity assays for optimization or structure-activity relationship studies.
- Availability of clear efficacy data in at least one relevant model system, with adequate power and methods.
- Demonstration of diagnostic or prognostic prediction in at least one relevant disease model.
- Demonstration of initial phases of prototype development and/or software development.
- Demonstration of access to data or tools needed to generate a knowledge product that will inform patient care.
- **Product Development:** The program expects award recipients to submit or obtain an Investigational New Drug/Investigational Device Exemption (IND/IDE) application to the FDA, or must transition the product to clinical practice or to the intended end user, by the end of the period of performance. Examples of the type of activity expected for this stage of product development include, but are not limited to:
 - Confirming efficacy and/or safety of therapeutic modalities (agents, delivery systems, and chemical modification of lead compounds) using established or validated preclinical systems.
 - Implementing full-scale Good Manufacturing Practice production of therapeutics and/or delivery systems for use in advanced preclinical and initial clinical trials.
 - Validating pharmacologic agents through absorption, distribution, metabolism, excretion, and toxicity studies.
 - Developing pharmacologic agents to IND stage for initiation of phase 1 clinical trials.
 - Developing prototype devices to IDE stage or abbreviated IDE stage for initiation of clinical trials.
 - Optimizing diagnostic or treatment devices for field deployment.
 - Performing retrospective clinical studies to inform clinical care.
 - Developing clinical decision-making tools to the clinical testing stage.
 - Conducting clinical research to validate a diagnostic strategy.
- **Relevance to Military Health:** The program expects awards to address relevance to the health care needs of military Service Members, Veterans and their Families. The PRMRP encourages applicants to consider the following characteristics as examples of how a project may demonstrate relevance to military health:
 - Explanation of how the project addresses an aspect of the target disease/condition/technology that has direct relevance to the health of military Service Members, Veterans and their Families.
 - Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to benefit the civilian population and also address a military need.
 - Use of military or Veteran populations, samples, or datasets in the proposed research, if appropriate.
 - PIs are encouraged to integrate and/or align their research projects with DOW and/or VA research laboratories and programs. Collaboration with the DOW and/or U.S. Department

Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

of Veterans Affairs (VA) is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOW and VA areas of research interest or potential opportunities for collaboration can be found in [Appendix 10](#) of the GAI.

3.2.3. Other Important Considerations for the Technology/Therapeutic Development Award

Applications to the TTDA must support translational product development. [Clinical trials](#) are not allowed within this funding opportunity; however, noninterventional [clinical research](#) studies are allowed. For help determining whether the proposed study meets the definition of a clinical research study or a clinical trial, refer to these [case study examples](#). Applicants seeking funding for basic research or clinical trials should consider one of the other FY26 PRMRP program announcements being offered. For information about these award mechanisms, see information contained in the [FY26 PRMRP Research Development Pipeline](#).

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the [STROBE](#) and [ARRIVE 2.0](#) guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the VA and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.4. Funding Details

[Period of Performance](#): The maximum period of performance is **4** years.

[Cost Cap](#): The application's total costs budgeted for the entire period of performance should not exceed **\$5.6M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **4** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

- Costs for up to two investigators to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY26 PRMRP Technology/Therapeutic Development Award.

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.
- Tuition.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a **pre-application** submitted via the Electronic Biomedical Research Application Portal ([eBRAP](#)) and a **full application** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.



Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.



4.2. Pre-Application Components

Pre-application submissions must include the following components.

Letter of Intent (one-page limit): Provide a brief description of the research to be conducted. Include the FY26 PRMRP portfolio, congressionally directed [FY26 PRMRP Topic Area](#), FY26 PRMRP continuum of care category, and [FY26 PRMRP Strategic Goal](#) under which the application will be submitted.

Select the appropriate mechanism option as described in [Section 5.3.1. Pre-Application Submission](#).

4.3. Full Application Components

Each application submission must include the completed full application package for this program announcement. See [Appendix 1](#) for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form (Grants.gov submissions only):



IMPORTANT: When completing the SF424 R&R, enter the **eBRAP log number** assigned during pre-application submission into **Block 4a – Federal Identifier**.

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the [formatting guidelines](#) in the GAI.

- **Attachment 1: Project Narrative (18-page limit): Upload as “ProjectNarrative.pdf”.**



Describe the proposed project in detail using the outline below.

- **Background:** Describe the product to be developed. The application must provide sound scientific rationale behind the proposed work, including relevant literature citations. Describe previous experience most pertinent to the project to demonstrate feasibility. **Include relevant preliminary data and/or promising preclinical findings that demonstrate proof of concept of the product or a prototype/preliminary version of the product. Preliminary data should be appropriate for the proposed stage of development and include the following as appropriate: proof of identity and purity; demonstrate selectivity; demonstrate diagnostic or**

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information


prognostic prediction in at least one relevant disease model; demonstrate existence of a prototype, demonstrate access to data or tools that will be required; demonstrate availability and/or feasibility of assays; show efficacy in an appropriate model system, etc. The data may be unpublished or from published literature. Unpublished preliminary data should originate from the laboratory of the PI or a member of the study team.

- **Hypothesis/Objective:** State the hypothesis to be tested and/or the objective(s) to be reached. Describe how the proposed research addresses a congressionally directed [FY26 PRMRP Topic Area](#). Additionally, describe how the proposed research project addresses one of the [FY26 PRMRP Strategic Goals](#).
- **Specific Aims:** Concisely explain the project's specific aims. These aims should agree with the primary aims and associated tasks described in the Statement of Work (SOW). If the proposed work is part of a larger study, present only the aims that this DOW award would fund.
- **Research Strategy and Feasibility:** Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail for analysis. Provide a well-developed, well-integrated research strategy that supports the translational feasibility and promise of the approach. Define the specific study outcomes and how they will be measured. Address potential problem areas and present alternative methods and approaches. Describe how data will be collected and handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, and identification of primary endpoints/outcomes. Consult appropriate [guidelines](#) to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported. Describe interactions with regulatory agencies as appropriate for the product under development.
 - Describe the statistical methodology and analysis plan including how it supports the stated hypothesis or objective. Include a description of the power analysis and whether it determined experimental population numbers; if not, justify why the power analysis is not essential to the statistical evaluation. Additionally, state whether the study will include univariate, bivariate, or multivariate analyses. State the variables to be used in the main analysis; include covariates and how the data will be adjusted to account for covariates, if applicable. Stratification of data (if applicable) should be described and justified.
 - If animal studies are proposed, briefly describe the key elements of the study/studies as they relate to the overall project. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study's relevance to human biology. Describe the randomization and blinding procedures for the study and any other measures to be taken to minimize effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
 - If human participants, human biological samples, or datasets will be used, describe the study population and include a detailed plan for the recruitment of human participants or the acquisition of samples/datasets. Describe the availability of the proposed study population and past successes in recruiting similar populations. If active-duty military, military Families, and/or Veteran population(s) or datasets will be used in the proposed research project, describe

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

the feasibility of accessing the population(s)/dataset(s). ***This award may not be used to conduct clinical trials.***

- **Inclusion of Women and Minorities (only required if [clinical research is proposed](#)):** Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial, and ethnic group, and an accompanying rationale for the selection of participants. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex, race, and ethnicity should be provided as part of the application's Supporting Documentation ([Attachment 2](#)). Refer to the [CDMRP Directive on Inclusion of Women and Minorities as Subjects in Clinical Research](#) for additional information.
- **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".** 

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).
- **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
- **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.
- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Support:** Provide individual letters as follows:
 - Letters of Collaboration (if applicable): Provide letters from collaborating individuals/organizations.
 - Letter of Eligibility Confirmation (required): Provide a letter from the Department Chair or equivalent confirming the PI meets [eligibility criteria](#) and has necessary resources.
 - Letters of Access (if applicable): Provide a letter from the lowest-ranking person with approval authority confirming participation of intramural DOW collaborator(s), access to access to military populations, databases or DOW resources. Additionally, provide a letter indicating access to VA military populations, databases or resources, provide a letter signed by the VA Facility

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

- **Inclusion Enrollment Report (only required if [clinical research is proposed](#)):** Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the "[Public Health Service \(PHS\) Inclusion Enrollment Report](#)", a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement.
- **Sex as a Biological Variable Strategy (two-page limit):** Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the [CDMRP Directive on Sex as a Biological Variable in Research](#) for additional information.
- **Research Sharing Plan:** Describe the type of data or research resources (e.g., biospecimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Do not submit a copy of the National Institutes of Health Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.

Refer to the [CDMRP Directive on Sharing Data and Research Resources](#) for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Use of DOW Resources or VA Resources (if applicable):** If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

understanding or other agreements required to access and publish data. Refer to the GAI, [Appendix 4](#), for additional considerations.

- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.** 

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** Present the scientific rationale behind the proposed research project.
- **Relevance to Topic Area:** State the congressionally directed [FY26 PRMRP Topic Area](#) and [FY26 PRMRP Strategic Goal](#) that will be addressed by the project. The topic area and strategic goal should be phrased exactly as they appear in section 3.2.1 and paraphrasing should be avoided. Additionally, describe how the proposed research project will address the stated congressionally directed [FY26 PRMRP Topic Area](#) and [FY26 PRMRP Strategic Goal](#).
- **Hypothesis/Objective(s):** State the hypothesis to be tested and/or objective(s) to be reached.
- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Describe the study design, including appropriate controls.
- **Relevance to Military Health:** Describe how the study is relevant to military health.

- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** 

The lay abstract should address the points outlined below *in a manner that is readily understood by readers without a background in science or medicine*. Avoid overuse of scientific jargon, acronyms and abbreviations. **Do not duplicate the technical abstract.**

- State the congressionally directed [FY26 PRMRP Topic Area](#) and [FY26 PRMRP Strategic Goal](#) that will be addressed by the project. The topic area and strategic goal should be phrased exactly as they appear in section 3.2.1 and paraphrasing should be avoided. Additionally, describe how the proposed research project will address the stated congressionally directed [FY26 PRMRP Topic Area](#) and [FY26 PRMRP Strategic Goal](#).
- Summarize the objectives and rationale for the proposed research.
- What population will the research help, and how will it help them?
- What are the potential applications, benefits and risks of the anticipated outcomes?
- What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?
- What is the potential benefit of the proposed study and the anticipated outcomes to Service Members, Veterans and/or their Families?

- **Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.** 
Refer to eBRAP for the [Suggested SOW Format](#).

For guidance on preparing the SOW, refer to the [Example: Assembling a Generic Statement of Work](#). [Clinical trials](#) are not allowed under this mechanism, but the [Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work](#) may

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

be appropriate for [clinical research](#) studies. Use whichever example is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

- **Attachment 6: Impact Statement (one-page limit): Upload as “Impact.pdf”.** The impact statement summarizes the potential short-term impact of the proposed research. **The statement should address the points outlined below written in a manner that is readily understood by readers without a background in science or medicine.**
 - Explain how the proposed research project will address a critical problem or question in one of the congressionally directed [FY26 PRMRP Topic Areas](#). Additionally, describe how the project addresses one of the [FY26 PRMRP Strategic Goals](#).
 - **Describe the short-term impact:** Detail the anticipated outcome(s)/product(s) (knowledge and/or material) that will be directly attributed to the results of the proposed research. Describe how the results of the research will impact the field of study and/or improve patient care in the near term as compared to current practice or currently used treatments. If the proposed research will affect a subset of the total population affected by the disease or condition, provide sufficient rationale for focusing on the subset.
- **Attachment 7: Relevance to Military Health Statement (one-page limit): Upload as “MilRel.pdf”.** **Attachment 7 will be available for programmatic review only.**
 - Describe how the proposed study is responsive to the health care needs of military Service Members, Veterans and their Families. Provide information about the incidence and/or prevalence of the disease or condition in the general population, as well as in military Service Members, Veterans and their Families. If the planned use of the product is to support the Warfighter, explain how the product meets the needs and requirements for use in the deployed setting.
 - If active-duty military, military Families, and/or Veteran population(s) or dataset(s) will be used in the proposed research project, describe the population(s)/dataset(s) and the appropriateness of the population(s)/dataset(s) for the proposed study. If a non-military population will be used for the proposed research project, explain how the population simulates the targeted population (i.e., military Service Members, Veterans and their Families).
 - If applicable, show how the proposed research project aligns with DOW and/or VA areas of research interest. Provide a description of how the knowledge, information, products, or technologies gained from the research could be implemented in a dual-use capacity to benefit the civilian population and address a military need, as appropriate.
- **Attachment 8: Post-Award Transition Plan (three-page limit): Upload as “Transition.pdf”.** Discuss the anticipated methods and strategies necessary to move the anticipated research outcome (e.g., intervention, product, methodology, finding) to the next phase of development (e.g., clinical trials, commercialization and/or delivery to the civilian or military market), assuming a positive outcome from the proposed clinical trial. Investigators are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. Applicants are encouraged to explore developing relationships with industry and/or other funding agencies or investors

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

to facilitate moving the product into the next phase of development when preparing the transition plan. ***The post-award transition plan should:***



- Name the project’s anticipated research outcomes including knowledge products and/or clinical products for development. A “knowledge product” is a non-material product that aims to transition into medical practice, training, tools, or to support material solutions; and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.
 - Include a timeline with defined milestones describing the logical next steps to advance the research outcome to the next stage of clinical development/ implementation/dissemination. Include steps regarding Regulatory Agency approval, as appropriate.
 - Describe collaborations and other resources (e.g., clinical partners, commercial partners, manufacturing partners, clinical practice guideline development/execution committees, training providers/resources) that are in place or will be established to execute the steps described above. Include a discussion of the funding strategy necessary to transition the research outcome to the next level of investigation, development, and/or commercialization. The discussion should include potential opportunities for securing funding through commercial sponsorship, venture capital, federal or nonfederal funding opportunities, or other relevant resources.
 - As appropriate, discuss ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award. Include a plan for resolving intellectual and material property issues among participating organizations. If the intellectual property rights are not owned by the applicant, PI, or a member of the study team, then describe the planned next steps necessary to make the product available to the target population.
 - Provide a plan for resolving intellectual and material property issues among participating organizations. The plan must be agreed to by all participating organizations for resolving intellectual and material property issues, including rights to publish, ownership of inventions, licensing terms, and government access rights.
- **Attachment 9: Animal Research Plan (three-page limit): Upload as “AnimalResPlan.pdf”. (*Attachment 9 is only applicable and required for applications proposing animal studies.*)**

If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the [ARRIVE guidelines 2.0](#) (Animal Research: Reporting *In Vivo* Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the Institutional Animal Care and Use Committee. The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:

- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology.
- Summarize the procedures to be conducted. Describe how the study will be controlled.

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
- Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
- Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).
- **Attachment 10: Prior Outcomes Statement (if applicable; one-page limit): Upload as “Outcomes.pdf”. Attachment 10 will be available for programmatic review only.**
If applicable, list all of the PI’s prior or in-progress CDMRP/PRMRP research projects/ awards, including resulting publications, abstracts, patents or other tangible outcomes. Only research and outcomes directly relevant to this application should be listed.
- **Attachment 11: Representations (Grants.gov submissions only): Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the [Required Representations](#) document available on eBRAP. 
- **Attachment 12: Suggested Intragovernmental/Intramural Budget Form (if applicable): Upload as “IGBudget.pdf”.** If an [intramural DOW organization](#) will be a collaborator in the performance of the project, complete a separate budget for that organization using the [Suggested Intragovernmental/Intramural Budget](#) form available on eBRAP. 

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.



Grants.gov



eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) (if applicable, Grants.gov submissions only)

Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, [DoD Instructions 3200.12](#) will be requested.



The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526 PRMRPTTDA from [Grants.gov](#) or [eBRAP](#), depending on which submission portal will be used.


5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), [SAM.gov](#), and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration. i

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI through [eBRAP](#). i

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during [the full application submission process](#). The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information


pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the [eBRAP Help Desk](#) if any changes need to be made.


When starting the pre-application, PIs should select the correct option appropriate to their pre-application:

- Select the FY26 PRMRP portfolio addressed by the proposed research.
- Select the congressionally directed [FY26 PRMRP Topic Area](#) addressed by the proposed research.
- Select the FY26 PRMRP continuum of care category addressed by the proposed research.
- Select the [FY26 PRMRP Strategic Goal](#) addressed by the proposed research.


Changes to any of the above selections between the pre-application submission and full-application submission require an email to the [eBRAP Help Desk](#).

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace. 

eBRAP Submissions: Only [intramural DOW organizations](#) may submit full applications through eBRAP. 

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. 
The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the [application verification period](#) ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in [Section 1, Basic Information](#).

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the [CDMRP's Directive on Research Duplication](#).

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.



Members of the FY26 PRMRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members **may** provide [letters](#) to confirm [PI eligibility](#) and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the [FY26 PRMRP Programmatic Panel members](#) can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in [Section 9.2, Administrative Actions](#).

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

Pre-applications submitted to this funding opportunity are used for program planning purposes only (e.g., reviewer recruitment) and will not be screened.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are listed in decreasing order of importance:

- **Impact**

- To what extent the proposed research project addresses the applicant-selected congressionally directed [FY26 PRMRP Topic Area](#), and to what extent the proposed research impacts a critical problem or an important scientific question relevant to that topic area.
- To what extent the proposed research project addresses the applicant-selected [FY26 PRMRP Portfolio-Specific Strategic Goal](#).
- To what extent the anticipated outcomes of the proposed study will have the potential to improve patient outcomes.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- If applicable, to what extent the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- To what degree the proposed project will make a significant impact on the lives of relevant patient populations in the short term.
- **Research Strategy and Feasibility**
 - How well the scientific rationale supports the project and its feasibility, as demonstrated by a critical review and analysis of the literature, promising preclinical findings, sound scientific rationale, and demonstrated proof of concept.
 - To what extent the preliminary data supports that the development of a potential clinical product has already been initiated by the study team, has passed the initial discovery stage, and has near-term potential for clinical translation or testing in clinical trials.
 - How well the hypotheses/objectives, experimental design, and methods have been developed; and how well they support completion of the aims and clinical translation of the product.
 - To what extent the data will be collected and analyzed in a manner consistent with the study aims.
 - For studies proposing [clinical research](#), the degree to which the plan to study patient populations is appropriate and feasible, and whether the application provides evidence of availability and access to the necessary study populations and/or resources.
 - [If applicable](#), whether the strategy for the inclusion of women and minorities and the distribution of proposed enrollment are appropriate for the proposed research.
 - To what extent the plan for sharing of project data and research resources is appropriate and reasonable, and includes dissemination to affected communities, study participants and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.
 - How well potential problems are identified and alternative approaches are addressed.
 - To what extent the proposed timeline for completion of the research is reasonable.
 - For studies involving the recruitment of human participants, whether the inclusion and exclusion criteria for the participants are sound.
 - How well studies are designed to achieve reproducible and rigorous results, including the choice of model, statistical methodology and plan, power analysis, and the endpoints/outcomes to be measured.
 - If applicable, whether the strategy for the inclusion of women and minorities and the distribution of proposed enrollment are appropriate for the proposed research. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement.
 - Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study, or whether the justification for a single-sex study is sufficiently strong.
- **Post-Award Transition Plan and Regulatory Strategy**
 - To what extent the anticipated outcomes will support the translation of promising preclinical findings to the next stage of development (clinical trials, commercialization,

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

and/or delivery to the civilian or military market) after successful completion of the award.

- If applicable, whether data will be appropriately reported and documented to support a regulatory filing with the FDA.
- Whether the identified post-award steps for development and/or plans for commercialization are realistic.
- Whether the funding strategy described to bring the product to the next level of development (e.g., specific potential industry partners, specific funding opportunities to be applied for) is reasonable and realistic.
- Whether the regulatory strategy and the development plan to support the proposed product label, if applicable, are appropriate and well-described.
- If applicable, whether the proposed collaborations and other resources for providing continuity of development of knowledge products (including proposed development or modification of clinical practice guidelines and recommendations, provider training materials, patient brochures, and other clinical support tools, scientific journal publications, models, simulations, and applications) are established and/or achievable.
- Whether the schedule and milestones for bringing the anticipated product to the next phase of development through to achieving a clinically meaningful outcome (clinical trials, transition to industry, delivery to the military or civilian market, incorporation into clinical practice, or approval by the FDA) are achievable. Whether the potential risk analysis for cost, schedule, manufacturability, and sustainability is realistic and reasonable.
- If applicable, to what degree the intellectual and material property plan is appropriate.
- **Personnel**
 - How appropriate the expertise and the levels of effort are for successful conduct of the proposed work.
 - How the background and expertise of the PI and other key personnel demonstrate their ability to perform the proposed work.
 - How the PI's record of accomplishment demonstrates their ability to accomplish the proposed work.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Budget**
 - Whether the budget is appropriate for the proposed research.
- **Environment**
 - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
 - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
- **Application Presentation**
 - To what extent the writing, clarity and presentation of the application components influence the review.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 PRMRP, as evidenced by the following:
 - Adherence to the intent of the funding opportunity
 - Relative impact
 - Relevance to the congressionally directed [FY26 PRMRP Topic Areas](#)
 - Relevance to the [FY26 PRMRP Strategic Goals](#)
 - Relevance to military health
 - Program portfolio composition
 - Relative outcomes from the PI's previous CDMRP-/PRMRP-funded research (if applicable)

6.3. Application Review and Selection Process

6.3.1. Pre-Application

There is no review and selection process for pre-applications submitted to this funding opportunity. ***CDMRP will NOT provide an invitation to submit a full application after pre-application submission.*** Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in [Section 6.2.3, Programmatic Review](#).*** Additional information about the two-tier process used by the CDMRP can be found on the [CDMRP website](#).

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a [limited time period](#) based on the fiscal year of the funds.

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the [DOD Component Decision Matrix](#) must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | [Federal Award Notices](#) | Post-Award Requirements | Other Information


7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the PRMRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable [database](#).

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official. 

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | [Post-Award Requirements](#) | Other Information

8. Post-Award Requirements


8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding [administrative requirements](#) and [national policy requirements](#).

Refer to full text of the latest [DoD R&D Terms and Conditions](#) and the [DHACA Terms and Conditions](#) for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee, IRB or Ethics Committee (EC) review. 

8.2. Reporting

Annual technical progress reports as well as a final technical progress report will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An [Award Expiration Transition Plan](#), using the template available on eBRAP, must be submitted with the final progress report.

PHS Inclusion Enrollment Reporting (***required for research proposing [clinical research](#)***): Enrollment reporting on the basis of sex, race, and/or ethnicity will be required with each annual and final progress report. The [PHS Inclusion Enrollment Report](#) is available on eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than \$10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable [Representations](#).

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

8.3. Additional Requirements

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.



An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- The Pre-application was not submitted.
- The Project Narrative exceeds the page limit.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 PRMRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the [CDMRP website](#).
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization):
(a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.
- The application fails to conform to this program announcement description.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- The application fails to address one of the congressionally directed [FY26 PRMRP Topic Areas](#).
- The application fails to address one of the [FY26 PRMRP Strategic Goals](#).
- The investigator is named as PI on more than one application submitted to the FY26 PRMRP. If more than one pre-application is submitted naming the same PI to the FY26 PRMRP, then the first submission will be accepted and the remaining will be administratively withdrawn.
- The PI does not meet the [eligibility criteria](#).
- The application does not include preliminary data demonstrating proof of concept of the product or a prototype/preliminary version of the product.
- The application proposes a clinical trial.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

9.2.5. Other Funding Opportunities

The PRMRP is committed to leveraging efforts with other funding organizations to accelerate progress in research. At the time of funding notifications, the PRMRP may inform highly rated, unfunded applicants about opportunities to provide their PRMRP applications and peer review summary statements to non-governmental and other governmental funders, who will determine the specific criteria for funding consideration.

Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded
SF424 Research & Related Application for Federal Assistance (Grants.gov submissions only)	<input type="checkbox"/>
Summary (Tab 1) and Application Contacts (Tab 2) (eBRAP submissions only)	<input type="checkbox"/>
Attachments	
Project Narrative – Attachment 1, upload as “ProjectNarrative.pdf”	<input type="checkbox"/>
Supporting Documentation – Attachment 2, upload as “Support.pdf”	<input type="checkbox"/>
Technical Abstract – Attachment 3, upload as “TechAbs.pdf”	<input type="checkbox"/>
Lay Abstract – Attachment 4, upload as “LayAbs.pdf”	<input type="checkbox"/>
Statement of Work – Attachment 5, upload as “SOW.pdf”	<input type="checkbox"/>
Impact Statement – Attachment 6, upload as “Impact.pdf”	<input type="checkbox"/>
Relevance to Military Health Statement – Attachment 7, upload as “MilRel.pdf”	<input type="checkbox"/>
Post-Award Transition Plan – Attachment 8, upload as “Transition.pdf”	<input type="checkbox"/>
Animal Research Plan (if applicable) – Attachment 9, upload as “AnimalResPlan.pdf”	<input type="checkbox"/>
Prior Outcomes Statement (if applicable) – Attachment 10, upload as “Outcomes.pdf”	<input type="checkbox"/>
Representations (Grants.gov submissions only) – Attachment 11, upload as “RequiredReps.pdf”	<input type="checkbox"/>
Suggested Intragovernmental/Intramural Budget Form (if applicable) – Attachment 12, upload as “IGBudget.pdf”	<input type="checkbox"/>
Additional Application Materials	
Research & Related Senior/Key Person Profile (Expanded)	<input type="checkbox"/>
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	<input type="checkbox"/>
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	<input type="checkbox"/>
Research & Related Budget	<input type="checkbox"/>
Project/Performance Site Location(s)	<input type="checkbox"/>
Research & Related Subaward Budget Attachment(s) (if applicable)	<input type="checkbox"/>

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

Appendix 2. Acronym List

ARRIVE	Animal Research: Reporting of In Vivo Experiments
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FDA	U.S. Food and Drug Administration
FY	Fiscal Year
GAI	General Application Instructions
IDE	Investigational Device Exemption
IND	Investigational New Drug
IRB	Institutional Review Board
LOI	Letter of Intent
M	Million
MIPR	Military Interdepartmental Purchase Request
ORRC	Office of Research and Regulatory Compliance
PANDAS	Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus
PANS	Pediatric Acute-Onset Neuropsychiatric Syndrome
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
PRMRP	Peer Reviewed Medical Research Program
R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
STROBE	STrengthening the Reporting of OBservational studies in Epidemiology
TTDA	Technology/Therapeutic Development Award
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs

Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

Appendix 3. Change Log

May 12, 2026

- Section 4.3, page 27: Added Attachment 9: Animal Research Plan
- Section 4.3, page 28: Updated Prior Outcomes Statement attachment number
- Section 4.3, page 28: Updated Representations attachment number
- Section 4.3, page 28: Updated Suggested Intragovernmental/Intramural Budget Form attachment number